Unique ID issued by UMIN | UMIN000027871 |
---|---|
Receipt number | R000031910 |
Scientific Title | The development of the transhepatic porto-systemic venous shunt(THPVS) for the portal hypertension |
Date of disclosure of the study information | 2017/06/22 |
Last modified on | 2019/06/26 06:59:47 |
The development of the transhepatic porto-systemic venous shunt(THPVS) for the portal hypertension
The development of the transhepatic porto-systemic venous shunt(THPVS) for the portal hypertension
The development of the transhepatic porto-systemic venous shunt(THPVS) for the portal hypertension
The development of the transhepatic porto-systemic venous shunt(THPVS) for the portal hypertension
Japan |
portal hypertension
Gastroenterology | Hepato-biliary-pancreatic medicine |
Others
NO
To evaluate the safety of the newly-developed transheparic porto-venous shunt(THPVS) for the patients with the refractory ascites, pleural effusion or gastrointestinal hemorrhage due to portal hypertension.
Safety
Phase I
severe or unexpected adverse events within 4 weeks
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
1.Insert the basket snare catheter into the hepatic vein from internal jugular vein.
2.Puncture the portal vein and insert the basket snare catheter into the portal vein.
3.Puncture the two basket snares with Chiba needle with "gun sight" method.
4.Insert the guidewire from the needle into the portal vein.
5.Catch the guidewire with the snare catheter and pull the guidewire out of the body.
6.Retrieve the needle and catch the same guidewire with the snare catheter from the jugular vein.
7.Pull out the guidewire from the jugular vein.
8.Expand the intrahepatic pathway with the balloon catheter.
9.Put the metallic stentgraft through the intrahepatic pathway.
* Measure the portal pressure before and after the procedure.
20 | years-old | <= |
120 | years-old | >= |
Male and Female
1.The patient with the refractory ascites or pleural effusion or gastrointestinal hemorrhage with portal hypertension.
2.Patients without thrombus in the intended hepatic vein or portal vein.
3.Patients without malignant tumor on the puncture line.
4.
1)white blood count:>=2000/mm3
2)platelet:>=50000/mm3
3)total serum bilirubin:<=3.0mg/dl
5.The MELD-Na score <= 17
1.Patients with unpuncturable organ on the puncture line on images.
2.Patients with obvious tendency of bleeding or coagulation disorder.
3.Patients with antiplatelet, thrombolysis or anticoagulation therapy.
4.Patients who are judged inappropriate by the principal investigator.
9
1st name | Eiji |
Middle name | |
Last name | Sugihara |
Osaka general medical center
Division of diagnostic imaging
537-8511
3-1-56, Bandaihigashi, Sumiyoshi, Osaka
06-6692-1201
eiji.sja2@gmail.com
1st name | Eiji |
Middle name | |
Last name | Sugihara |
Osaka general medical center
Division of diagnostic imaging
537-8511
3-1-56, Bandaihigashi, Sumiyoshi, Osaka
06-6692-1201
eiji.sja2@gmail.com
Osaka general medical center
no
Self funding
Osaka general medical center
3-1-56, Bandaihigashi, Sumiyoshi, Osaka
06-6692-1201
kenkyusien@gh.opho.jp
NO
2017 | Year | 06 | Month | 22 | Day |
Unpublished
Enrolling by invitation
2017 | Year | 05 | Month | 31 | Day |
2017 | Year | 06 | Month | 22 | Day |
2017 | Year | 06 | Month | 22 | Day |
2019 | Year | 06 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031910